Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment.
about
Galectin-3 and Beclin1/Atg6 genes in human cancers: using cDNA tissue panel, qRT-PCR, and logistic regression model to identify cancer cell biomarkersAnti-cancer activities of pH- or heat-modified pectinNuclear transport of galectin-3 and its therapeutic implicationsLectin array and glycogene expression analyses of ovarian cancer cell line A2780 and its cisplatin-resistant derivate cell line A2780-cp.Hormesis, cell death and aging.Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cellsCell death in disease: from 2010 onwardsGalectin-3 Overrides PTRF/Cavin-1 Reduction of PC3 Prostate Cancer Cell MigrationGalectin-3 augments tumor initiating property and tumorigenicity of lung cancer through interaction with β-catenin.Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine.Regulation of p73 activity by post-translational modifications.Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death.Galectin-3: a possible complementary marker to the PSA blood testThe inhibitory effects of a rhamnogalacturonan I (RG-I) domain from ginseng pectin on galectin-3 and its structure-activity relationship.Galectin-3 regulates p21 stability in human prostate cancer cells.Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression.Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment.Galectins as new prognostic markers and potential therapeutic targets for advanced prostate cancers.Lectins with potential for anti-cancer therapy.Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.Micro-ribonucleic acid 29b inhibits cell proliferation and invasion and enhances cell apoptosis and chemotherapy effects of cisplatin via targeting of DNMT3b and AKT3 in prostate cancerGalectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment.Comparative studies on the anti-tumor activities of high temperature- and pH-modified citrus pectins.Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin.Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications.Immunotherapy in lung cancer: the potential of cancer stem cells in future therapies.Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.
P2860
Q21134996-B2853B4D-D33C-466B-8D3C-FA94DE17133DQ26821932-FA7DEAEE-B0BB-4FAF-851C-2991F7446056Q26824889-571A8257-0480-4B9E-994B-AB1F14DCD2C8Q33722717-BB489F2F-9962-4AA8-8615-3AE19B833A64Q34217654-DD9BA14B-150E-46EB-BD49-8A44AD2E2F60Q34654834-AEF5E129-BAC3-4784-BCEE-2F35E088BF4FQ35269870-92593CA8-1BBE-40A9-9F1F-FBD7F2CE3D54Q35622432-3ADC57A3-6C18-4AD3-A662-F8F860A3D42CQ35741579-8901FCCD-B150-4B9D-A2E8-141B7F26461EQ35763903-9E0CC316-EFE3-4E52-8585-480279A23ADFQ35865249-8A39D471-B183-4184-BED8-49072294B998Q36440083-F2F51176-7BC8-49A4-A7E5-5281E9D40ED7Q37038393-E4C57E00-11CB-479D-8F13-2122C55AFEC8Q37333778-A1815304-DBF4-4C1E-8CE8-23CE90543C0CQ37542482-D21E59C0-3DD7-465E-8269-C7A0D9C90F26Q37716533-2F270583-C52D-40D3-919A-CD49BE16197DQ38019412-B9002648-D789-4232-A3C3-AEC03BF478FDQ38160862-B9CD2417-633E-4CB9-B816-94358344064DQ38366653-A2E66C00-B991-4498-AA31-869519D70E7AQ38783325-7C4E01BB-9EA7-4BBD-B5BB-900A05ACE873Q38898187-4A3FAA13-9A7E-43C2-9223-52D0F786449DQ39114955-FD24A738-8D38-4F19-AFAF-80228EE1B001Q39152161-C82946BA-448A-4221-8A62-F4CC233EE362Q40970978-F2B9473F-6ACD-478A-BCE7-294C9ED5B05FQ42632659-80A69FA9-E44E-4FC9-A237-99AD6991DD82Q44022392-5D95D12E-68F6-448F-A1A1-EF7B37B5C82DQ48270428-586DFAE0-F487-4B85-B037-42E4D1731514
P2860
Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Calpain activation through gal ...... cells to cisplatin treatment.
@ast
Calpain activation through gal ...... cells to cisplatin treatment.
@en
Calpain activation through gal ...... cells to cisplatin treatment.
@nl
type
label
Calpain activation through gal ...... cells to cisplatin treatment.
@ast
Calpain activation through gal ...... cells to cisplatin treatment.
@en
Calpain activation through gal ...... cells to cisplatin treatment.
@nl
prefLabel
Calpain activation through gal ...... cells to cisplatin treatment.
@ast
Calpain activation through gal ...... cells to cisplatin treatment.
@en
Calpain activation through gal ...... cells to cisplatin treatment.
@nl
P2093
P2860
P356
P1476
Calpain activation through gal ...... r cells to cisplatin treatment
@en
P2093
P2860
P356
10.1038/CDDIS.2010.79
P577
2010-11-18T00:00:00Z